Product Description: PCSK9-IN-29 is a lipid-lowering agent. PCSK9-IN-29 can increase low-density lipoprotein receptor (LDLR) protein expression and decrease PCSK9 protein expression in hepG2 cells. PCSK9-IN-29 can reduce the levels of serum LDL-C, TC, and liver enzyme ALT in crab eating macaques fed a high-fat diet, lower body weight and fat, and increase bone mineral content. PCSK9-IN-29 can be used for research on non-alcoholic fatty liver disease and obesity[1].
Formula: C26H26FNO6S
References: [1]Liu, jing wen, et al. 治疗 NASH、NAFLD 和肥胖症的化合物、组合物和方法. China, CN115279755A. 2022-11-01.
CAS Number: 1233353-86-0
Molecular Weight: 499.55
Compound Purity: 99.44
Research Area: Metabolic Disease; Inflammation/Immunology
Solubility: DMSO : 2 mg/mL (ultrasonic;warming;heat to 60°C)
Target: LDLR;PCSK9